BTKi are considered to be the beacon of hope in the MS community, as they are supposed to specifically target and slow down the creeping parts of MS. BTKi are very small molecules that go directly into the brain and thus, unlike B-cell-depleting therapies, influence microglia in addition to B-cell modulation. Fenebrutinib belongs to this class of active substances. Professor Mathias Mäurer talks about new developments regarding Fenebrutinib in the video.
What’s special about Fenebrutinib is that it wasn’t tested against a placebo or a rather weakly effective MS medication, but against Ocrelizumab. Ocrelizumab is an active substance in effectiveness category 3 for relapsing MS and so far the only approved medication for primary progressive MS (PPMS), where it is only approved in the early stages, not later when many nerve cells have already died off.
In this so-called head-to-head study, Tolebrutinib was able to keep up with Ocrelizumab in terms of slowing down disability progression in people with primary progressive MS.
Professor Mathias Mäurer talks in this video interview about
- the phase 3 study,
- how to evaluate the results,
- which side effects have occurred so far,
- how Fenebrutinib could be used and
- when Fenebrutinib could be approved in Europe at the earliest.
This post was translated from German to English with the help of AI.
